Analysts Set Expectations for VolitionRx FY2024 Earnings

VolitionRx Limited (NYSE:VNRX) – Equities researchers at Zacks Small Cap raised their FY2024 EPS estimates for shares of VolitionRx in a research report issued to clients and investors on Wednesday, December 4th. Zacks Small Cap analyst S. Ralston now anticipates that the company will post earnings of ($0.28) per share for the year, up from their previous estimate of ($0.29). The consensus estimate for VolitionRx’s current full-year earnings is ($0.31) per share. Zacks Small Cap also issued estimates for VolitionRx’s Q4 2024 earnings at ($0.06) EPS.

Several other research firms have also commented on VNRX. Benchmark reissued a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com assumed coverage on shares of VolitionRx in a report on Friday. They issued a “sell” rating for the company.

VolitionRx Stock Down 6.2 %

Shares of NYSE:VNRX opened at $0.59 on Monday. The company has a market capitalization of $54.68 million, a price-to-earnings ratio of -1.64 and a beta of 1.17. The firm has a 50 day moving average of $0.69 and a 200 day moving average of $0.67. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC increased its holdings in VolitionRx Limited (NYSE:VNRX) by 15.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 730,448 shares of the company’s stock after purchasing an additional 95,900 shares during the quarter. Geode Capital Management LLC owned 0.79% of VolitionRx worth $439,000 at the end of the most recent reporting period. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.